SMART Medical Systems Ltd., a developer and manufacturer of innovative endoscopy products, today reported positive data from a multicenter clinical study (NCT 04708951) comparing the adenoma detection rate (ADR) of its FDA-cleared G-EYE® balloon technology against ENDOCUFF VISION® (ECV) technology in patients undergoing screening or surveillance colonoscopy. Results from this randomized trial, the first head-to-head comparison of these two colonoscopy mechanical enhancement devices, showed that the ADR, particularly for advanced and large adenomas, was higher for the G-EYE® balloon than for the ECV attachment. Seth Gross, MD, Professor, Department of Medicine at NYU Grossman School of Medicine, Clinical Chief, Division of Gastroenterology and Hepatology at NYU Langone Health, and co-author on the abstract, presented the data in an oral session at ACG 2021, which is taking place October 22-27 in Las Vegas (ACG 2021, Presidential Plenary Session 1, Abstract #S233).
Trending
- With AI and biomarkers, selfies could support doctors’ decision-making (Healthcare IT News)
- AI-Based Ambient Scribes May Reduce Physician Documentation Time, Burnout (Gastroenterology Advisor)
- ChatGPT’s AI Health-Care Push Has a Fatal Flaw (Bloomberg)
- Exploring trust factors in AI-healthcare integration: a rapid review (Frontiers in Artficial Intelligence)
- ChatGPT’s AI Health-Care Push Has a Fatal Flaw (Bloomberg)
- AI is speeding into healthcare. Who should regulate it? (The Harvard Gazette)
- Ethical and Legal Considerations for Responsible Use of AI in Clinical Gastroenterology (American Journal of Gastroenterology)
- Google Launches MedGemma 1.5 & MedASR to Broaden Healthcare AI Capabilities (Digital Health News)
